Previous 10 | Next 10 |
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it is scheduled to participate in a fireside chat at the 2023 UB...
2023-11-02 16:51:04 ET Mirum Pharmaceuticals press release ( NASDAQ: MIRM ): Q3 GAAP EPS of -$0.57. Revenue of $47.7M (+153.7% Y/Y). For further details see: Mirum Pharmaceuticals GAAP EPS of -$0.57, revenue of $47.7M
- Third quarter 2023 total revenue of $47.7 million - Completed acquisition of CHENODAL® and CHOLBAM® - Announced positive Phase 3 RESTORE study results evaluating CHENODAL (chenodiol) in patients with CTX; NDA filing expected in H1 2024 - Conference call to provide business updat...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Mirum Pharmaceuticals Inc. (MIRM) is expected to report $-0.64 for Q3 2023
- Late-breaker poster presentation accepted featuring LIVMARLI ® data showing long-term maintenance of response in patients with PFIC - Four poster presentations will highlight LIVMARLI PFIC data and volixibat proof-of-concept trial data in intrahepatic cholestasis of pregnancy ...
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2023 financial results on Thursday, November 2 nd , 2023. Mirum will also host a conference call to discuss the third quarter 2023 financial results and recent corporate progress. Conference call ...
2023-10-17 17:25:51 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease Franchise Mirum Pharmaceuticals, Inc. (MIRM) Q2 2023 Earnings Call Transcript Mirum Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call ...
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has extended the review of the Supplemental New Drug Application (sNDA) for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with progressive...
2023-10-13 17:12:53 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease Franchise Seeking Alpha’s Quant Rating on Mirum Pharmaceuticals For further details see: Mirum Pharmaceuticals to sell 7.94M shar...
News, Short Squeeze, Breakout and More Instantly...
Mirum Pharmaceuticals Inc. Company Name:
MIRM Stock Symbol:
NASDAQ Market:
Mirum Pharmaceuticals Inc. Website:
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC)...
European Commission grants LIVMARLI marketing authorization for treatment of PFIC in patients three months and older. Approval follows positive opinion from CHMP concluding LIVMARLI’s clinical benefit over existing therapy in PFIC. LIVMARLI also received positive COMP opinion recom...
Submission based on the positive Phase 3 RESTORE study Mirum holds orphan designation for chenodiol in CTX Potential to have first and only therapy indicated for CTX in the US Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the submission of a new drug application (ND...